Grifols to invest Euro 110m in new Los Angeles plant
As part of plans to expand and improve facilities in the US and Spain, Barcelona-based blood derivatives group Grifols is to invest Euro 110m in a new Los Angeles plant to manufacture the company's next generation intravenous immunoglobulin, Flebogamma.
As part of plans to expand and improve facilities in the US and Spain, Barcelona-based blood derivatives group Grifols is to invest Euro 110m in a new Los Angeles plant to manufacture the company's next generation intravenous immunoglobulin, Flebogamma.
Production is expected to begin in 2012, according to president Victor Grifols. The US now accounts for more than 30% of the group's sales, he added.
The facility is part of a €400m investment plan that includes new production lines at the company's Barcelona complex for the biological adhesive fibrin glue, which Grifols hopes to market from 2012. It will also expand the filtering process there for blood derivatives and double annual plasma production to 4m litres by 2013.
The FDA recently approved Grifols' new purpose-built facilities at the Los Angeles plant designed to ensure maximum safety in the aseptic filling, sterilisation and lyophilisation (freeze drying) stages of plasma products Factor VIII, Factor IX and Profilnine.
Along with the improvements at the Los Angeles plant, the company's goals in the US include opening new plasma centres and a new laboratory for analysis in Texas.